Anaveon AG
Immunotherapies for cancer
We are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
13.07.2026
Deep-tech and biotech startups strengthen their leadership teams (startupticker.ch)
22.05.2026
Swiss biotechs progress across cardiology, oncology and allergy clinical programs (startupticker.ch)
08.04.2026
Swiss startups appoint new CEOs and senior hires across biotech, AI and proptech (startupticker.ch)
06.01.2025
Executive reshuffle in four startups (startupticker.ch)
02.08.2024
Seasoned chairpersons and board members back life sciences startups (startupticker.ch)
Last Tweets
No milestones
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Anaveon AG
Immunotherapies for cancer
Website:
www.anaveon.com
Headquarter:
Basel
Foundation Date:
December 2017
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
Support received
